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Abstract 
BACKGROUND: Tuberculosis (TB) and HIV co-infection is association with significant morbidity 
and mortality, especially in young children. Prevention of tuberculosis in children with HIV is a 
global health priority and is best achieved through a combination of antiretroviral therapy (ART) 
and isoniazid preventive therapy (IPT). Current WHO guidelines recommend 6 months of IPT for 
all HIV-infected children older than 1 year without TB disease; up to 3 years is recommended in 
high TB prevalence areas. Although both ART and IPT can cause liver injury, data on the safety 
of IPT in HIV-infected children accessing ART is limited, and no published data exist on the 
hepatotoxicity risk of prolonged IPT. This thesis aims to address these knowledge gaps. 
METHODS: The main aim of this thesis was to investigate the incidence of severe liver injury in 
HIV-infected children receiving IPT.  The specific objectives were to:  (1) Present a structured 
research proposal and plan; (2) Conduct a structured review of published literature on severe 
liver injury among children receiving IPT, with a specific focus on those with HIV; and (3) 
Present the findings of a prospective study evaluating risk of liver injury among HIV-infected 
children receiving prolonged IPT. A randomized, placebo-controlled trial of IPT (the “INH-
study”) commenced in December 2002, in Cape Town, South Africa. Participants were HIV-
infected children. Placebo was discontinued in May 2004, due to a marked survival benefit 
among children receiving IPT. Thereafter, all children receiving placebo were switched to IPT 
and followed until December 2007, to assess safety and adherence. Alanine transaminase (ALT) 
was measured at baseline, six-monthly and during illness: an increase ≥10-fold the upper limit 
of normal defined severe liver injury.  
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RESULTS: A structured literature search strategy was developed and implemented by one 
author. Apart from the published findings of this thesis project, only two other published 
papers presented risk estimates of liver injury in HIV-infected children receiving IPT (range of 
0.4-5% of study population). No other published, prospective data on IPT-related liver injury in 
HIV-infected children older than one year or in symptomatic HIV-infected children were found. 
In the INH study, 297 of 324 children (91.6%) received IPT, and 207(63.9%) received ART. 
Although 16 children developed severe liver injury while receiving IPT, isoniazid was considered 
causative in only five cases (1.7%). No child developed hepatic failure; one died of an unrelated 
cause. All surviving children subsequently tolerated IPT.  
CONCLUSIONS:  Taken together with other published studies of IPT in children, these findings 
suggest that long-term IPT has a low toxicity risk in pediatric populations irrespective of HIV or 
ART status.  
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1. BACKGROUND 
Tuberculosis (TB) and HIV co-infection is associated with significant mortality and 
morbidity; young, HIV-infected children are particularly vulnerable to the 
development of TB disease, with poor outcomes in the absence of antiretroviral 
therapy1-3.  Although antiretroviral therapy (ART) or isoniazid preventive therapy 
(IPT) given individually significantly reduce TB risk, there is evidence that IPT given 
with ART has even greater efficacy in both adults and children1, 2. The World Health 
Organization (WHO) has identified the “three I’s” (IPT, intensified case finding and 
infection control) as key to reducing the incidence of TB among people living with 
HIV 3. Current WHO guidelines recommend 6 months of IPT for all HIV-infected 
children older than 1 year without TB disease, even in the absence of a known TB 
contact; up to 3 years is recommended in high TB prevalence areas4, 5. Despite 
these recommendations, uptake of IPT for HIV infected individuals remains 
disappointingly low, even in high TB burden areas9. Drug side effects, including liver 
injury, are known barriers to successful isoniazid preventive therapy among 
adults10, 11.  Isoniazid can cause idiosyncratic liver injury12. Its predominant 
metabolizing pathway is acetylation by N-acetyltransferase 2 (NAT2); liver toxicity 
is mostly attributed to metabolites such as hydrazine12.In general, idiosyncratic 
drug induced liver injury (DILI) is thought to result from a complex “multi-hit” 
process, where drug-specific upstream injury is exacerbated or ameliorated by less 
specific downstream factors13, 14.  Known predisposing factors for isoniazid induced 
liver injury can be categorized accordingly: drug-specific risk factors include higher 
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dosages and polymorphisms of NAT212. During TB treatment, daily dosing appears 
to confer higher risk than intermittent dosing12. Previously described 
“downstream” factors include malnutrition, other hepatotoxic drugs (such as 
nevirapine and pyrazinamide), viral hepatitis, and in adults, age and alcoholism13, 14. 
Children generally tolerate isoniazid better than adults. Although death and hepatic 
failure can occur15, less than 0.8% of HIV-uninfected children experience moderate 
to severe liver injury6-10, compared to 0.1- 6.4% of HIV-uninfected adults8, 11, 12. 
Although the independent effect of HIV on DILI is not yet fully understood, it is 
biologically plausible that the chronic state of immune activation associated with 
HIV can predispose to idiosyncratic DILI13. In Botswana, HIV-infected adults 
receiving 6 months of IPT appeared to have a risk of liver injury similar to that of 
HIV-uninfected adults13, 14; another study described severe liver injury in a higher 
proportion (5.5%) of adults on a similar IPT regimen24. Data for HIV-infected 
children are limited. A retrospective cohort study reported severe liver injury in 5% 
of 112 HIV-infected children receiving IPT, most of which was ascribed to other 
causes such as viral hepatitis15. In a recent study of pre-exposure IPT used early in 
infancy, HIV-infected infants received isoniazid for up to 2 years; 0.4% developed 
significantly raised alanine transaminase (ALT), and 4.0% developed significantly 
raised aspartate aminotransferase (AST) 16. However, there are no published, 
prospective long-term data on liver injury in HIV-infected children older than 1 
year, or in symptomatic HIV-infected children, who commence IPT.  As risk factors 
for idiosyncratic DILI are dynamic13, 14, it is possible that the cumulative risk for 
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isoniazid induced liver injury is greater during long-term exposure, as was observed 
among HIV-infected adults receiving 3 to 6 years of IPT24. There are no published 
studies reporting adverse effects of long-term exposure to isoniazid in children. 
This study aims to investigate the incidence, predictors and outcomes of severe 
liver injury in a cohort of HIV-infected infants and children receiving IPT for up to 
five years. 
2. STUDY OBJECTIVE, AIMS & HYPOTHESES 
Study objective: 
To investigate the incidence, predictors and outcomes of severe liver injury in a 
cohort of HIV-infected children enrolled in a 5-year prospective trial of isoniazid 
preventive therapy (IPT). 
Specific aims: 
1) To describe the incidence, clinical presentation and outcomes of severe 
liver injury among study participants, including liver injury 
probably/possibly related to isoniazid preventive therapy 
2) To identify predictors of severe liver injury  
Hypotheses: 
1. Isoniazid-induced severe liver injury is rare among children with HIV.  
2. The incidence of severe liver injury is higher among children receiving 
isoniazid daily, compared to thrice weekly; it is also higher among those 
receiving anti-retroviral therapy and anti-tuberculosis therapy containing 
rifampicin/pyrazinamide, and in children with more advanced HIV disease. 
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3. METHODS 
3.1 Study design 
Secondary analysis of data obtained, with permission, from a closed clinical trial 
database (“Long Term Study of 2 Isoniazid (INH) Prophylactic Regimens With 
Concomitant Trimethoprim-Sulphamethoxazole (TMP-SMX) in HIV-infected 
Children - Impact on Morbidity, Mortality, Bacterial Resistance and Incidence of 
Tuberculosis”); registered as Clinical Trials NCT00330304, with Principle 
Investigators Prof Heather J Zar, University of Cape Town and Professor Mark F 
Cotton, Stellenbosch University27.  
The original study was conducted prospectively at two sites in Cape Town, South 
Africa, between December 2002 and December 2007. The study had a factorial 
design:  participants were randomized to receive either isoniazid or placebo (first 
level of randomization, double-blind with allocation concealment), with 
trimethoprim- sulphamethoxazole (TMP-SMX). The second level of randomization 
(allocation not concealed) was to either a daily or thrice weekly dosing schedule for 
all study drugs (isoniazid with TMP-SMX, or placebo with TMP-SMX).   
Incidence of severe liver injury was an a priori secondary outcome specified in the 
original trial protocol, as approved by the Ethics Committees of University of Cape 
Town (HREC REF 057/2002) and Stellenbosch University. The primary outcome for 
the IPT component of the study was mortality; the sample size achieved (324 
participants) was sufficiently powered to detect a significantly lower mortality risk 
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in the IPT group as compared to the placebo group. This result has been 
published28. 
Sample size and statistical power 
Although the primary focus of this secondary outcome analysis is descriptive, some 
comparisons will be made between different subgroups. With a sample size of only 
324, it is anticipated that only marked differences will be statistically detectable. 
However, a secondary power analysis will not be conducted, as the sample size was 
calculated for a different outcome, and the study is closed. As currently 
recommended, 95% confidence intervals will be used to demonstrate the precision 
achieved for all estimates29,30.  
3.2 Study population 
HIV-infected children older than 8 weeks of age and weighing more than 2.5kg, resident within 
the Cape Metropole area, and whose parents/legal guardian provided informed consent, were 
eligible for enrolment if the caregivers had access to transport. Exclusion criteria included: 
chronic diarrhea, current use of (or need for) IPT according to national TB control guidelines, 
history of hypersensitivity to isoniazid or allergy to sulphur drugs, severe anemia, neutropenia, 
and/or thrombocytopenia, irreversible kidney failure and/or clinical hepatitis.  Asymptomatic 
children with significant baseline ALT elevation were thoroughly investigated; after full 
biochemical recovery, study drugs were systematically introduced under close monitoring.  
Children younger than 18 years with HIV infection (hence, vulnerable population) 
were the subjects of this study, as the aim was to identify efficacious strategies to 
lower mortality and morbidity risk for this particular population. Of the 339 
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children enrolled, 324 will be included in this analysis: 15 will be excluded, as 10 
children ultimately tested HIV-negative, and 5 were lost to follow-up within a 
month of randomization. These are the same 324 study participants who were 
included in other published analyses from the same database28, 31, 32. 
3.3 Recruitment and enrolment 
For the original study, children were recruited from the two tertiary hospitals 
(RCWMCH and TCH), as well as New Somerset and Paarl hospitals; there were also 
study eligibility assessment referrals from various district hospitals and clinics. 
Details of this process have been published28. 
3.4 Research procedures and data collection methods 
Extensive clinical history, clinical examination and laboratory testing were 
conducted on all enrolled participants at baseline, and repeated according to the 
study protocol at specified follow-up times. Extensive clinical data were collected 
onto standard forms every three months; at every six month interval, chest X-rays 
and laboratory investigations were also conducted, and results captured. 
Relevant to this study, alanine transaminase (ALT) was measured at baseline and 
six-monthly; children on ART also had ALT measured 1 and 3 months after 
enrolment. Other baseline and six-monthly investigations have been described 
elsewhere17, 18. Tests were repeated more frequently if clinically indicated.  All 
deaths were investigated by accessing clinical records, or if unavailable, by verbal 
autopsy where feasible.  
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Toxicity 
Toxicity events were graded according to the Division of AIDS (DAIDS) toxicity 
criteria19. For liver injury, an ALT 10 times the upper limit of normal was defined as 
a grade 3 event; above 15-fold increase was considered grade 4. Gender and age-
specific reference ranges were used to define the upper limit of normal, according 
to local laboratory practice. Each toxic event was assessed as definitely, probably, 
possibly or unrelated to study drugs.  
Data capture 
All information was entered by hand onto standardized paper forms designed by 
the study team leaders. Electronic data capture was done in intervals by two 
experienced data capturers, at both sites, onto a central database. Before final 
analyses commenced, all data entries were double checked and discrepancies 
resolved by an external data management expert in consultation with the project 
manager. The database is now closed.  
3.5 Data safety and monitoring 
A data safety and monitoring board (DSMB) comprising international and South 
African experts reviewed safety and progress of the study based on three- to six-
monthly interim data analyses28, 31, 32.  The placebo arm of the study was 
terminated by the DSMB after 19 months of enrolment due to the early survival 
benefit observed on IPT28; the DSMB continued to monitor the study until isoniazid 
was discontinued for all participants at the earliest study visit following December 
2007. 
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This secondary outcome analysis will be supervised by two experienced 
researchers, as indicated previously. 
3.6 Data analysis 
Data will be extracted from the closed database, without any personal identifiers, 
by the study data manager. The data will be analyzed and saved on the personal 
computer of Dr Stanzi le Roux; no other person will have access to the data. The 
data, and results from analyses, will also be saved onto an external hard drive for 
back-up purposes. 
The main outcome of interest will be severe liver injury, defined as a grade 3 or 4 
elevation in ALT at any time during follow-up. To address all the study aims, three 
levels of analysis will be conducted, using Stata version 10.0 (Stata Corporation, 
College Station, Texas, USA): 
(1) Proportions 
Risk will be summarized as the proportion of children who ever developed severe 
liver injury, and also as the proportion of children who ever developed severe liver 
injury possibly/probably related to isoniazid. 
(2) Survival analysis: Kaplan-Meier method with incidence rates(IR)  and 
incidence rate ratios (IRR) 
The Kaplan-Meier method34 will be used to analyze time to first episode of severe 
liver injury. To account for potential changes in clinical management of a patient 
following severe liver injury, follow-up time will be censored at the first episode; 
for those who were event-free, last known time alive will used.  The main predictor 
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will be dosing schedule (thrice weekly compared to daily). Using crude IRR, risk for 
severe liver injury will be compared between dosing schedules (intent-to-treat 
analysis) and between different categories of drug exposure (as-treated analysis).  
(3) Survival analysis: Cox proportional hazards regression 
Predictors of severe liver injury will be analyzed with Cox proportional hazards 
regression analysis34.  The following potential confounders will be assessed: 
baseline age, Centers for Disease Control and Prevention (CDC) clinical and immune 
categories, CD4 cell percentage (CD4%), weight-for-age Z-score, gender and study 
site. Current drug exposure will be modeled as a time-varying covariate. Study site 
will be adjusted for in all analyses, as randomization was stratified by site. After 
conducting an exploratory data analysis, likelihood ratio tests and Akaike’s 
Information Criterion will be used for model building34.  Effect modification by 
dosing schedule will be tested for. Model checking will be done using residuals 
analysis; the proportional hazards assumption will be tested with the Grambsch-
Therneau test34. Statistical tests will be two-sided at alpha=0.05.  
3.7 Other methodological aspects 
A description of risks and benefits, the informed consent processes and 
reimbursement details of the original study have been provided and approved 
previously (HREC REF 057/2002). 
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3.8 Privacy and confidentiality 
No personal identifiers will be present in the data used for analysis. 
3.9 Contributions, authorship and acknowledgements 
The principle investigator of this secondary study, Dr Stanzi le Roux, originally participated in 
data collection as medical officer for the UCT site. She will be conducting the data cleaning, 
analysis and writing the mini-thesis protocol, literature review and journal-ready manuscript 
under the supervision of Professors Zar and Myer during her time as a registered MPH student 
(2009-2013).  Her two supervisors are Prof Heather J Zar (principle investigator of the overall 
study) and Prof Landon Myer (convener of the MPH Clinical Research track). Along with 
Professors Mark F Cotton and H Simon Schaaf, Professor Zar conceived the original study, wrote 
the protocol and grants applications, obtained funding and supervised the study. Dr Carl 
Lombard was the trial statistician.  
In the event of publication of this secondary outcome analysis, authorship will be attributed 
according to standard authorship guidelines.  
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1. Summary: 
INTRODUCTION:  Isoniazid preventive therapy (IPT) is an effective strategy to reduce 
the incidence of tuberculosis in both HIV-infected and HIV-uninfected children. 
However, isoniazid has been reported to cause idiosyncratic liver injury. The risk for IPT-
related liver injury is considered low in HIV-negative children; its risk among HIV-
infected children, especially those receiving antiretroviral therapy (ART), is not well-
established. 
OBJECTIVES: To summarize, evaluate and compare published data on the risk of liver 
injury among both HIV-infected and HIV-uninfected children receiving IPT, and to 
identify knowledge gaps and further research needs. 
STUDY ELIGIBILITY CRITERIA (DESIGN, POPULATION & INTERVENTION): Studies 
presenting longitudinal data on hepatic adverse events among children (0-18 years) 
receiving isoniazid monotherapy as tuberculosis prevention were eligible. 
STUDY APPRAISAL: Potential sources of bias evaluated: study design; a priori case 
definitions of liver injury; degree and type of toxicity monitoring; method for attribution 
of causality; assessment and reporting of loss to follow-up and adherence. 
RESULTS: Four hundred and ninety studies were found through 3 database searches 
(Medline, Scopus and Web of Science; an additional 8 records were identified through 
reference list searches and review articles. Titles, abstracts and full-text articles were 
evaluated sequentially, with ineligible articles discarded at each stage. Twenty-four 
articles were included for review, of which 3 were in HIV-infected children. The studies 
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were variable in dosages, duration of IPT; definitions of liver injury; type and degree of 
monitoring; assessment of loss to follow-up and adherence; ages of patients, and 
concurrent viral hepatitis screening. Only 2 studies were prospective, randomized and 
placebo-controlled. The estimated risk for severe IPT-related liver injury in HIV-
uninfected children ranged from none (INH given for 6 months at 5 mg/kg), to 1.78% 
(INH given for 6 months at 10-20 mg/kg). Risk estimates for IPT-related liver injury 
among HIV-infected children ranged from 0.4% to 7%; the calculation of 7% risk 
included cases where liver injury was ascribed to other causes. Overall, sixteen cases of 
hepatic failure were described, none among HIV-infected children. Viral hepatitis was 
excluded in very few children. Overall, intensive laboratory monitoring and higher 
dosage of isoniazid appeared to increase the risk for liver injury. In general, HIV-
infection did not appear to increase risk of IPT-related DILI. 
LIMITATIONS: The limited scope of the review methodology increases the risk of 
selective reporting bias, publication bias and reviewer bias. However, the reviewed 
publications extended over several decades of global IPT use, and included several 
studies with sample sizes over 1000; thus the potential impact of any missed reports is 
likely to be minimal. Given the heterogeneity of monitoring and liver injury definitions 
used, biased assessment of outcomes is highly likely, especially in the retrospective 
studies; misclassification bias could have influenced risk estimates in either direction. 
However, the monitoring and to a lesser degree the definitions of liver injury were 
aligned with national and international guidelines of tuberculosis prevention at the time 
of the research. The lack of placebo-controlled studies also increased risk for 
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misclassification bias due to faulty attribution of causality. However, much toxicity 
literature depends on post-marketing reports, and given the efficacy of IPT in children, 
placebo controls would have been unethical in most of the research settings.  
CONCLUSIONS & IMPLICATIONS:  IPT-related liver injury appears to occur infrequently 
among HIV-negative children; severe liver injury is extremely rare, especially with 
frequent monitoring and early interruption of therapy in the event of symptomatic 
hepatitis. Viral hepatitis should be considered in children with apparent drug-induced 
hepatotoxicity. The risk for IPT-related liver injury in HIV-infected children does not 
appear to be higher than in HIV-negative children. However insufficient numbers of 
older children were evaluated in the three studies reporting risk of DILI in in HIV-
infected children to make meaningful comparisons. . As the global ART roll-out 
progresses, ongoing vigilance for liver injury is imperative as larger numbers of children 
will be receiving ART and INH simultaneously.  
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2. Literature review: 
2.1 INTRODUCTION 
Isoniazid has been successfully used as preventive therapy against active tuberculosis 
(TB) since its efficacy was established by large, controlled trials in the middle of the 20th 
century1-4; it remains the mainstay of treating latent tuberculosis infection (LTBI) 
globally5. 
Appropriate use of preventive therapy requires a careful balance of potential benefits 
and risks6. Children, particularly immune-compromised children such as those with HIV 
or under the age of 5 years, are at substantial risk of progressing from LTBI to severe 
forms of tuberculosis, with substantial associated mortality7, 8. Although isoniazid 
preventive therapy (IPT) can significantly reduce this risk2, 9, 10, some concerns exist 
regarding potential hepatotoxicity, as isoniazid can cause idiosyncratic drug-induced 
liver injury (DILI)11, 12. Although fatal IPT-related DILI has been described13, the risk is 
considered low in children not infected with HIV14. Applying current concepts of 
idiosyncratic liver injury processes, children infected with HIV may however be at higher 
risk for severe IPT-related liver injury than their HIV-uninfected counterparts. 
Idiosyncratic DILI appears to result from a succession of events, described as a “multi-hit 
process”, where a potentially mild to moderate DILI (“upstream” insult) may be 
amplified or suppressed in the presence of other factors (through “downstream” 
pathways)15, 16. Liver insults can therefore wax and wane over time as environmental 
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and other risk factors change15. Known risk factors for DILI are viral infections such as 
Hepatitis A, B or C; concurrent use of other hepatotoxic agents; and malnutrition17-19.  
Most of the world’s HIV-infected children live in sub-Saharan Africa20, where almost 
50% of the population live in poverty21. In such settings, both viral hepatitis and 
childhood malnutrition are common21, 22. Furthermore, anti-retroviral therapy, itself 
potentially hepatotoxic17, is increasingly available for HIV-infected children, and may 
amplify any IPT-initiated DILI. It is also biologically plausible that HIV infection itself may 
increase the risk for DILI, given the altered cytokine milieu of chronic viral infections16. 
As global efforts intensify towards improving child survival and the reduction of HIV-
associated tuberculosis, increasing numbers of children access both ART and IPT20, 23. 
Understanding the IPT-associated risk for liver injury in children with HIV is crucial to 
enable a considered weighing of the risks and benefits of this combined approach. 
Objectives: 
This literature review seeks to summarize, evaluate and compare published data on the 
risk of liver injury among both HIV-infected and HIV-uninfected children receiving IPT, 
and to identify knowledge gaps and further research needs. 
2.2 METHODS 
i. Information sources and literature search: 
Three databases (Medline, Scopus and Web of Science) were searched for articles 
published from the earliest date through October 2013. The search strategies were 
adapted to each database, but combined three main themes: “isoniazid” in combination 
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with terms for prophylaxis, and terms for hepatotoxicity. The MEDLINE search strategy 
is outlined below: 
1. isoniazid 
2. prophylaxis OR “preventive therapy” OR chemoprevention OR treatment OR 
therapy 
3. hepatotoxicity OR “liver injury” OR “serious adverse events” OR “side effects” OR 
“liver toxicity” OR toxicity 
4. 1 AND 2 AND 3 
Bibliographies of selected review articles were screened14, 24-26, and expert opinion 
sought, to identify additional publications or studies. The searches were limited to 
English language articles reporting on children. 
ii. Eligibility criteria: 
Original articles reporting longitudinal data were included; thus eligible study designs 
were randomized controlled trials (RCTs) or quasi-RCTs, controlled interventional trials 
and both prospective and retrospective cohort studies. Studies reporting only adult data 
were excluded; the population of interest was children (≤ 18 years of age), irrespective 
of HIV status. Isoniazid used as monotherapy to prevent tuberculosis was the 
intervention of interest; studies reporting use of isoniazid in conjunction with other 
anti-tuberculosis agents were excluded, as were studies where isoniazid was used for 
other reasons. Eligible outcomes were any report (clinical or laboratory) of number of 
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hepatic adverse events, provided a denominator (total number of children exposed to 
isoniazid) was available for risk estimation.   
iii. Study selection: 
A single author evaluated all retrieved articles by title and abstract, retaining for full text 
review those without abstracts and those potentially eligible for inclusion. The same 
author conducted a full-text review of the retained articles, applying the a priori 
specified eligibility criteria outlined above.  
iv. Data collection and analysis: 
Structured, piloted forms were used to extract data including information on population 
ages, sample size, isoniazid dosage and duration, type and schedule of adverse event 
monitoring, clinical information on liver injury, study-specific definitions of 
hepatotoxicity, laboratory findings and risk estimates for liver injury (appendix 1). 
Populations of patients studied prior to 1990 were presumed to be HIV negative; if 
authors did not comment on HIV testing, a negative status was also assumed. Data on 
potential threats to validity were also extracted, including proportion lost to follow up, 
adherence and lack of allocation concealment where applicable. No meta-analysis was 
conducted, as study characteristics were heterogeneous.  
v. Study appraisal 
As recommended in the PRISMA (Preferred Reporting Items for Systematic review and 
Meta-analyses) guidelines27, risk of bias was considered at both the study and the 
outcome level. The following characteristics were systematically evaluated: the study 
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design (interventional vs. observational, prospective vs. retrospective; use of placebo; 
randomization and allocation concealment); whether there was an a priori definition of 
liver injury; how serious adverse events were monitored (actively or passively, by clinical 
parameters and/or laboratory tests); how causality was attributed (in particular, 
whether screening for viral hepatitis was performed); to what degree outcome 
ascertainment for children who were lost to follow up occurred; and whether 
adherence to medication was assessed and accounted for.  
2.3 SUMMARY OF FINDINGS AND INTERPRETATION 
i. Description of studies included 
Four hundred and ninety studies were identified through database searches (Medline, 
Scopus and Web of Science); an additional 8 records were identified through reference 
list searches, discussion with an expert, and review articles (figure 1). Four hundred and 
sixteen titles and abstracts were screened after the removal of duplicates; of these, 369 
records were excluded. Reasons for exclusion were: not providing numbers of IPT-
exposed children (no denominator for risk calculation, 4 publications), not providing 
information on hepatic toxicity (59), not investigating isoniazid monotherapy for TB 
prevention (194), not being an eligible article type (95) or study population not including 
children (17). Of 39 full-text articles reviewed, 15 more articles were excluded, for the 
same reasons (figure 1). Twenty-four studies were included for the review, of which 21 
were conducted in HIV-uninfected children, 2 in HIV-infected children and 1 in both HIV-
infected and HIV-uninfected children.  
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FIGURE 1.  Flow of information through literature review process: liver injury among children 
receiving isoniazid preventive therapy 
 
 
  
Records identified through database 
searching (N=490) 
Medline = 174 
Scopus = 258 
Web of Science = 58 
Additional records identified through 
other sources (N=8) 
 
(Reference list searches and review 
articles) 
Abstracts and titles screened after duplicates removed (N=416) 
Records excluded (n=369) 
Not in children = 17 
Not isoniazid monotherapy for 
tuberculosis prevention = 194 
Not hepatic toxicity = 59 
No denominator = 4 
Ineligible article type  
(e.g. review article) = 95 
Full-text articles assessed (N=39) 
Studies included in the review (N=24)* 
Studies of IPT in HIV infected children (n=3)* 
Studies with placebo comparison n=1* 
Prospective cohort studies n=1 
Retrospective cohort studies n=1 
 
*One study evaluated both HIV-infected and uninfected children 
and is presented in both groups 
 
Studies of IPT in HIV-negative/untested children (n=22)* 
Studies with placebo comparison n=2* 
Prospective cohort studies n=14 
Retrospective cohort studies n=6 
 
*One study evaluated both HIV-infected and uninfected children 
and is presented in both groups 
 
Articles excluded (n=15) 
Not in children = 2 
Not isoniazid monotherapy for 
tuberculosis prevention = 7  
Not hepatic toxicity = 0 
No denominator = 1 
Ineligible article type (e.g. review 
article) = 5 
Isoniazid 
& 
Liver/Toxicity/ 
Hepatotoxicity/ 
Injury/Serious adverse event 
& 
Limits: 
Children & Humans & English 
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The studies were variable regarding study design; population age; dosages and duration 
of IPT; definitions of liver injury; type and degree of monitoring; assessment of loss to 
follow-up and adherence; and use of viral hepatitis screening (tables 1-4). Two studies 
were prospective, randomized and placebo-controlled4, 28; only one of these provided an 
a priori definition for liver injury and conducted standardized serious adverse event 
monitoring28. 
a. Study designs, settings and populations 
Fourteen of the 22 studies in HIV-uninfected children were conducted in the United 
States of America (USA)4, 29-41, including the 5 studies with sample size of over 1000 
children. The large studies all included children younger than 5 years of age, although 
the proportions of very young children were usually not made explicit30.  Except for the 
randomized, placebo-controlled Public Health Service Trial4, the US-based studies were 
all observational. Smaller studies were conducted in Greece42, 43, Spain44, South Africa28, 
45, Iran46, Turkey47 and Canada48. Of these, only one was randomized with a placebo 
comparison28. The majority of the 20 observational studies were of prospective cohorts 
of children seen at tuberculosis clinics. 
All three of the studies conducted among HIV-infected children were South African, with 
median ages of 2 years or younger28, 49, 50. The study by Madhi et al28 was a randomized, 
placebo controlled trial, whereas the other 2 studies were observational, of which one 
was prospective. Although the latter had originally been designed as randomized and 
placebo-controlled, the placebo arm was discontinued early in the study, and 
randomization broken; hence the majority of IPT-exposure time was accrued under 
observational conditions.  
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TABLE 1: Liver injury among children with HIV status unknown/negative receiving isoniazid preventive therapy (IPT) at 5 mg/kg 
Authors 
Study design 
and 
attributes 
INH 
dosage 
and 
duration 
Patient 
numbers 
and ages 
Monitoring 
Viral hepatitis 
testing 
Clinical 
indicators of 
liver injury 
Study 
definition of 
hepato-
toxicity 
Summary 
of 
laboratory 
findings 
Timing of 
liver injury 
detection 
Risk of 
mild-
moderate 
liver injury 
Risk of 
severe 
liver 
injury 
Total risk 
of 
liver 
injury 
Outcomes 
Mount & 
Ferebee 3, 4 
1957 & 
1961 
(2 reports 
from one 
study) 
Randomized, 
placebo 
controlled 
Multi-site 
Blinded & 
allocation 
concealment 
4-6 mg/kg  
daily for 
12 months 
n=1394 
≥ 1 year; no 
upper limit 
given 
95% ≤ 11 
years 
Clinical: monthly 
pill collection and 
examination 
Not stated Nausea and 
vomiting in 2 
(0.14%); 
recurrence 
when re-
challenged 
Not stated n/a Not stated 0.14% 
(2/1394) 
None 0.14% 
(2/1394) 
Treatment 
discontinued in 2 cases 
No hepatic failure/ 
death due to IPT 
LTFU@12m: 0.5% 
Litt 37 
1976 
Prospective 
cohort, no 
placebo 
4-6 mg/kg 
daily for 
46 weeks 
n=178 
12-16 years 
 
Laboratory: Pre-
treatment and 
weekly liver 
function tests 
including ALT & 
AST 
Not stated No 
symptomatic 
cases 
Unclear; 
treatment 
discontinued 
in one 
adolescent 
with AST > 
1200 U/L 
14/155 
(9%) 
patients 
had 
increased 
AST overall 
Most 
within first 
10 weeks 
8.4% 
(13/155) 
0.6% 
(1/155) 
9% 
(14/155) 
Treatment 
discontinued in 1 case 
No hepatic failure/ 
death due to IPT 
% LTFU unclear 
Spyridis 43 
1979 
 
Prospective 
cohort, no 
placebo 
300 mg 
± 5 mg/kg 
daily for at 
least 
3 months 
n=239 
9-14 years 
Laboratory: Pre-
treatment and 
monthly ALT and 
AST 
Pre-treatment 
HBsAg; 
At liver injury: 
HBsAg 
repeated, EBV 
All negative 
No 
symptomatic 
cases 
Unclear; 
treatment 
discontinued 
for ALT/AST 
>100 U/L 
AST>40 U/L 
in 36/239 
(15%) 
ALT>30 U/L 
in 23/239 
(9.6%) 
Most 
within first 
8 weeks 
16.3% 
(39/239) 
0.8% 
(2/239) 
17.1% 
(41/239) 
Treatment 
discontinued in 2 cases 
No death/hepatic 
failure due to IPT 
% LTFU unclear 
Tortajada 44 
2005 
 
Prospective, 
randomized 
to INH or 
Rif/PZA 
No placebo, 
no allocation 
concealment 
5 mg/kg 
daily for 
6 months 
n=35 
1-19 years 
Laboratory: Liver 
enzyme tests at 2, 
4, 6 and 8 weeks 
Not routinely 
done 
No 
symptomatic 
cases 
AST or ALT ≥ 
5 times upper 
limit of 
normal 
No 
comment 
on low 
grade rise 
in trans-
aminases 
No liver 
injury 
detected 
None None None No treatment 
interruptions 
No death/hepatic 
failure due to IPT 
% LTFU of children 
unclear 
Marais 45 
2006 
 
Prospective 
cohort, clinic-
based 
No placebo 
5 mg/kg 
daily for 
6 months 
180 
<5 years 
Clinical: monthly 
pill collection 
Not stated No 
symptomatic 
cases 
Not stated None No liver 
injury 
detected 
None None None No treatment 
interruptions 
No death/hepatic 
failure due to IPT 
LTFU: 79% lost within 4 
months 
Aminzadeh4
6 2010 
Retrospective 
cohort 
No placebo 
5 mg/kg 
daily for 
3-6 
months 
15 
 <6 years 
Clinical: seen 3 
monthly 
 
Not stated No 
symptomatic 
cases 
Not stated Not tested No liver 
injury 
detected 
None None None No treatment 
interruptions 
No death/hepatic 
failure due to IPT 
% LTFU unclear 
Abbreviations: HIV, Human immunodeficiency virus; INH, isoniazid; n/a, not applicable; IPT, isoniazid preventive therapy; LTFU, loss to follow-up; mg/kg, milligram per kilogram; ALT, alanine transaminase; AST, aspartate 
aminotransferase; HBsAG, Hepatitis B surface antigen; EBV, Ebstein-Barr virus; Rif, Rifampicin; PZA, pyrazinamide 
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TABLE 2: Liver injury among children with HIV status unknown/negative receiving isoniazid preventive therapy (IPT) at 10 mg/kg 
Authors 
Study design 
and 
attributes 
INH 
dosage 
and 
duration 
Patient 
numbers and 
ages 
Monitoring 
Viral 
hepatitis 
testing 
Clinical 
indicators of 
liver injury 
Study 
definition 
of Liver 
injury 
Summary of 
laboratory 
findings 
Timing of 
liver injury 
detection 
Risk of mild-
moderate 
liver injury 
Risk of 
severe 
liver 
injury 
Total risk 
of  
liver injury 
Outcomes 
Beaudry 33 
1974 
 
Prospective 
cohort 
No placebo 
Incomplete 
data for 
65/434 (15%) 
patients; 
10 mg/kg 
daily for 
3-12 
months 
369 
1-18 years 
7 had raised 
AST pre-
treatment 
Laboratory: 
AST done pre-
treatment 
and after 8 
weeks; 
clinical visits 
at 2, 4, 8 and 
12 months 
HBsAg and 
EBV tested in 
“most” 
children with 
elevated AST; 
none tested 
positive 
No 
symptomatic 
cases 
AST > 95 U 
(2x ULN) 
AST > 50 U in 
25/369 (6.8%) 
AST> 95 U in 
4/369 
(1.1%) 
Within first 
2 months 
21/369 (5.7%) 4/369 
(1.1%) 
25/369 
(6.8%) 
Treatment 
interrupted in 4 
children; 3 restarted 
uneventfully. 
No death/hepatic 
failure due to IPT 
27/434 (6%) non-
compliant or LTFU 
Nakajo 38 
1989 
 
 
Retrospective 
cohort 
No placebo 
 
 
10 mg/kg 
daily for 
12 
months 
564 
3 months - 18 
years; mean 
of 8 years 
 
Clinical: seen 
monthly; liver 
function tests 
done if 
symptomatic 
Tested in 
child with 
raised trans-
aminases:  
HAV, HBV & 
EBV negative 
Nausea, 
vomiting, 
anorexia, 
malaise, and 
abdominal 
tenderness  
(all in 1 case)  
Symptoms 
(specified) 
and ALT 
and/or AST 
> 100 U ± 
increased 
TSB 
One child:  
AST 730 
ALT 1444 
Normal TSB; 
normalized 
within 4 
weeks 
6 weeks 39/564 (6.9%) 
symptoms 
compatible 
with liver 
injury but 
AST/ALT 
remained  
<100 
1/564 
(0.18%) 
40/564 
(7.1%) 
Treatment 
interruption in 1 
adolescent; failed 
re-challenge 
No death/hepatic 
failure due to IPT 
LTFU in 5% 
Palusci 40 
1995 
Retrospective 
cohort 
No placebo 
10 mg/kg 
daily for 
9 months 
318 
3 months to 
18 years 
Clinical: seen 
monthly; liver 
function tests 
done if 
symptomatic 
For one 
patient (with 
hepatic 
failure), all 
negative: 
HAV, HBV, 
HCV; CMV & 
EBV 
Abdominal 
pain (6); 
nausea/ 
vomiting (2); 
weight loss 
(1); 
↓appetite(1); 
jaundice (1) 
Not stated A child had 
hepatitis 
symptoms 
with AST 328 
U/l and ALT 
313 U/l 
 
4 months 10/318 (3.1%) 
symptoms of 
hepatitis 
But AST/ALT 
< 50 U/l 
1/318 
(0.3%) 
11/318 
(3.4%) 
Treatment 
interruption in 1 
adolescent with 
hepatic failure 
No deaths due to 
IPT. 
% LTFU not stated 
Spyridis 42 
2007 
Prospective 
cohort (9 
months of 
INH vs 3-4 
months of 
INH with Rif 
Quasi-
randomized, 
no allocation 
concealment 
No placebo 
10 mg/kg 
daily for 
9 months 
Total 232; 
< 15 years, 
mean age 9 
years, 15% <6 
years 
Only 200 
considered 
“compliant” 
 
Clinical: 
follow-up 
schedule not 
stated 
Not stated Nausea and 
epigastric 
pain in 
13/200 (6.5%) 
Symptoms 
with liver 
enzymes >3 
times ULN 
12/200 (6%) 
had increased 
liver 
enzymes, but 
all ≤ 3 times 
ULN 
Not stated 13/200 (6.5%) None 13/200 
(6.5%) 
No treatment 
interruptions 
No death/hepatic 
failure due to IPT 
Poor to moderate 
compliance in 34.5% 
% LTFU not stated 
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Authors 
Study design 
and 
attributes 
INH 
dosage 
and 
duration 
Patient 
numbers and 
ages 
Monitoring 
Viral 
hepatitis 
testing 
Clinical 
indicators of 
liver injury 
Study 
definition 
of Liver 
injury 
Summary of 
laboratory 
findings 
Timing of 
liver injury 
detection 
Risk of mild-
moderate 
liver injury 
Risk of 
severe 
liver 
injury 
Total risk 
of  
liver injury 
Outcomes 
Wu 32   
2007 
National 
retrospective 
cohort using 
data from 
transplant 
databases, 
physician 
surveys, 
literature 
searches and 
the CDC 
10 mg/kg 
daily for 
various 
durations 
216 776  
0-14 years 
 
 
Not possible 
to determine; 
children with 
liver failure 
had had 
clinical 
monitoring 
only 
Tested in all 
children with 
liver failure: 
HBV + (1) 
HAV + (1); 
CMV + (1); 
No child 
tested 
positive for 
HCV or EBV 
15 children 
on IPT 
presented 
with 
fulminant 
hepatic 
failure 
Hepatic 
failure 
Not stated Range: 6 
weeks to 
9 months 
Cannot be 
estimated 
from the data 
used 
3.2 per 
100 000 
child 
years 
Cannot be 
estimated 
from the 
data used 
15 cases of acute 
hepatic failure on 
IPT: 
3 (20%) survived 
without OLT 
7 (47%) survived 
with OLT 
5 (33%) died despite 
OLT 
Devrim 47 
2010 
Retrospective 
cohort 
No placebo 
Not 
stated† 
 
617 
ages not 
stated 
Not stated 
but most 
likely 
laboratory, 
based on 
results 
Not stated Not stated WHO 
toxicity 
grading 
used; test 
details not 
stated 
Grade I-II: 
6 (0.9%) 
Grade III: 2 
(0.33%); 
Grade IV: 9 
(1.5%) 
Not stated 6/617 (0.9%) 11/617 
(1.78%) 
17/617 
(2.8%) 
Not stated 
Abbreviations: HIV, Human immunodeficiency virus; INH, isoniazid; n/a, not applicable; IPT, isoniazid preventive therapy; LTFU, loss to follow-up; mg/kg, milligram per kilogram; ALT, alanine transaminase; AST, aspartate 
aminotransferase; HBsAG, Hepatitis B surface antigen; EBV, Ebstein-Barr virus; HAV, Hepatitis A virus; HBV, Hepatitis B virus; HCV, Hepatitis C virus; CMV, cytomegalovirus; ULN, upper limit of normal; TSB, total serum bilirubin; 
Rif, rifampicin; CDC, Centers for Disease Control & Prevention; WHO, World Health Organization; OLT, orthoptic liver transplantation  
† These children were most probably managed according to WHO treatment guidelines of 200651 (10mg/kg daily for 6 months)52 
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TABLE 3: Liver injury among children with HIV status unknown/negative receiving isoniazid preventive therapy (IPT) at 10-20 mg/kg daily or 20-30 mg/kg 
twice weekly 
Authors 
Study design 
and 
attributes 
INH dosage 
and 
duration 
Patient 
numbers 
and ages 
Monitoring 
Viral 
hepatitis 
testing 
Clinical 
indicators of 
liver injury 
Study 
definition of 
hepato-toxicity 
Summary of 
laboratory 
findings 
Timing of 
liver injury 
detection 
Risk of 
mild-
moderate 
liver injury 
Risk of 
severe 
liver 
injury 
Total risk 
of  
liver 
injury 
Outcomes 
Hsu 36  
1974 
Prospective 
cohort 
No placebo 
10-20 
mg/kg daily 
for 12 
months 
1487 
0.5 -15 
years; 
50% < 8 
years 
Clinical; seen 
3 monthly 
“Watchful 
vigilance” 
Not stated Rash, 
vomiting 
and/or 
diarrhea 
Not stated Not stated Not stated 4/1487 
(0.27%) 
None 4/1487 
(0.27%) 
No treatment 
interruptions 
No deaths/hepatic 
failure due to IPT 
% LTFU not 
stated; only 
those who 
completed 
therapy were 
included 
Kopanoff30 
1978 
Prospective 
multi-site 
surveillance 
cohort 
No placebo 
 
Not stated1 2473 
<20 years 
Clinical; seen 
monthly 
Not routinely 
done 
Not stated Probable/ 
Possible cases: 
variable cut-off 
for raised ALT 
depending on 
concomitant 
liver disease 
Not stated Not 
provided 
separately 
for children 
1 per 1000 
persons 
None 1 per 
1000 
persons 
No information 
on treatment 
interruption in 
children 
No deaths/ 
hepatic failure in 
children due to 
IPT 
% LTFU not 
stated; Non-
compliant 
patients 
screened for 
signs/ symptoms 
of hepatitis 
Rapp 41 
1978 
Prospective 
cohort study 
No placebo 
10-15 
mg/kg daily 
for 12 
months 
116  
<21 
years; 
 
 14/116  
<3 years 
of age 
Clinical and 
laboratory: 
ALT and TSB 
done at 
completion of 
treatment ± 
pre-
treatment ± 
at 6-20 weeks 
Not stated No 
symptomatic 
cases 
Not stated Increased ALT 
> ULN for age 
in 5/118 
(4.3%) tests 
done during 
treatment 
Not stated 5/118 
(4.3%) 
None 5/118 
(4.3%) 
No information 
regarding 
treatment 
interruption 
No deaths/ 
hepatic failure 
due to IPT 
LTFU: 14 patients 
not included in 
study due to non-
compliance 
(14/130, 10.8%) 
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Authors 
Study design 
and 
attributes 
INH dosage 
and 
duration 
Patient 
numbers 
and ages 
Monitoring 
Viral 
hepatitis 
testing 
Clinical 
indicators of 
liver injury 
Study 
definition of 
hepato-toxicity 
Summary of 
laboratory 
findings 
Timing of 
liver injury 
detection 
Risk of 
mild-
moderate 
liver injury 
Risk of 
severe 
liver 
injury 
Total risk 
of  
liver 
injury 
Outcomes 
Byrd 34 
1979 
Prospective 
cohort 
No placebo 
Not stated1  19  
<19 years 
Clinical and 
laboratory at 
monthly 
intervals 
Not stated Not stated AST > 5X ULN 
(defined as 100 
IU) 
No child had 
AST > 5X ULN 
No cases 
among 
children 
Unclear None 
 
Unclear Six treatment 
interruptions 
unrelated to liver 
function tests; 
reasons unclear 
No deaths/ 
hepatic failure 
due to IPT 
% LTFU not 
stated 
Dash 35 
1980 
Prospective 
cohort 
No placebo 
Not stated1  636  
<15 years 
Clinical: 
monthly 
visits; liver 
function tests 
done when 
indicated 
clinically 
Not stated Rash and 
malaise 
“most 
frequently 
reported” 
Mild, moderate 
and severe not 
differentiated; 
Cases were 
either 
“probable” or 
“possible” 
Not provided Not stated 
for children 
4 possible 
cases of 
hepatitis: 
4/636 
(0.6%) 
No 
probable 
cases of 
hepatitis 
in 
children 
4/636 
(0.6%) 
31 treatment 
interruptions (5%) 
No deaths/hepatic 
failure due to IPT 
LTFU % not stated but 
“dropout rate was… 
the least for those 
under 15…” 
Nolan 39 
1999 
Prospective 
cohort 
No placebo 
Not stated1  1468  
<15 years 
Clinical: 
monthly 
structured 
questionnaire 
For patients 
with 
symptoms: 
minimally, 
HAV, HBV and 
HCV tested 
(all negative) 
No 
symptomatic 
cases among 
those < 15 
years old 
Symptoms 
(specified);  AST 
≥ 5 times ULN ± 
raised TSB; and, 
clinical 
resolution after 
withdrawal of 
IPT 
No cases 
among 
children 
No cases 
among 
children 
No cases 
among 
children 
No cases 
among 
children 
No cases 
among 
children 
No treatment 
interruptions 
No death/hepatic 
failure due to IPT 
Overall LTFU: 35%; not 
available for 
paediatric subgroup. 
Hospitals’ discharge 
databases reviewed 
for data on outcomes 
LoBue 31 
2003 
Prospective 
cohort 
No placebo 
Not stated1 1277  
<14 years 
Clinical: 
monthly 
structured 
questionnaire 
Transaminase
s measured in 
high-risk 
patients 
Not stated No 
symptomatic 
cases among 
children 
Any 
signs/symptoms 
previously 
associated with 
INH, onset after 
IPT initiation, 
with no 
alternative 
cause found 
AND increased 
liver enzymes: 
AST/ALT > 5x 
ULN if 
asymptomatic 
OR AST/ALT >3x 
ULN if 
symptomatic 
No cases 
among 
children 
No cases 
among 
children 
No cases 
among 
children 
No cases 
among 
children 
No cases 
among 
children 
No treatment 
interruptions in 
children due to 
hepatotoxicity 
No deaths/ hepatic 
failure due to IPT 
26% of children did 
not complete the 
prescribed IPT course; 
no reasons stated 
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Authors 
Study design 
and 
attributes 
INH dosage 
and 
duration 
Patient 
numbers 
and ages 
Monitoring 
Viral 
hepatitis 
testing 
Clinical 
indicators of 
liver injury 
Study 
definition of 
hepato-toxicity 
Summary of 
laboratory 
findings 
Timing of 
liver injury 
detection 
Risk of 
mild-
moderate 
liver injury 
Risk of 
severe 
liver 
injury 
Total risk 
of  
liver 
injury 
Outcomes 
Minodier 48 
2010 
Prospective 
cohort 
No placebo 
10-15 
mg/kg daily 
for 6-9 
months 
545 
Mostly 
10 -12 
years old 
Clinical: seen 
at 1, 3, 6 and 
9 months 
Not stated Abdominal 
pain (4.7%), 
weight loss 
(2.8%), 
vomiting 
(1.9%) 
Not stated Not stated Not stated Not stated None Not 
stated 
Treatment 
interruptions: none 
recorded 
38.7% non-adherence; 
reasons not stated 
Madhi 28 
2011 
Randomized 
controlled 
trial with 
placebo; 
allocation 
concealment 
double-
blinded 
10-20 
mg/kg daily 
for 2 years 
403 HIV-
negative 
children 
in IPT 
group; 
Median 
(IQR) age 
96 (91-
120) days 
Clinical and 
laboratory at 
three-
monthly 
study visits 
including AST 
and ALT 
Not stated Not stated Grade III/IV 
increase in liver 
enzymes (> 5x 
ULN) 
Not stated Not stated Not stated ALT: 
3/403 
(0.7%) 
AST: 
8/403 
(2%) 
ALT: 
3/403 
(0.7%) 
(Placebo 
group, 
8/401 
(2%)) 
No treatment 
interruptions for 
hepatotoxicity 
No death/hepatic 
failure due to IPT 
LTFU: 56/403 (13.9%); 
placebo group had 
15% LTFU 
Cruz 29 
2013 
Retrospective 
cohort 
No placebo 
comparison 
20-30 
mg/kg bi-
weekly for 
3-9 months 
1337; 
0-18 
years 
 
Clinical; visit 
schedule not 
stated. 
Transaminase 
levels done 
for 
“abdominal 
complaints” 
Not stated Abdominal 
pain and/or 
vomiting in 
30 cases 
(2.2%) 
Transaminases 
> 3 times the 
ULN 
Transaminase
s done in 27 
children; 3/27 
had 
increases, 
ranges: 
AST 415-788 
ALT 408 - 884 
Mean time 
to onset of 
symptoms: 
1.6 months 
Not stated 3/1337 
(0.22%) 
Not 
stated 
Treatment 
interruptions: 22/1337 
(1.6%) 
No death/hepatic 
failure due to IPT 
19/1337 (1.42%) did 
not complete 
treatment 
1 Children in these studies were most likely managed according to recommendations of the Medical Section of the American National Tuberculosis and Respiratory Disease Association53, and would 
have received an INH dosage of 10-20 mg/kg or 10-15 mg/kg, for 9-12 months, as recommended in later documents of the American Thoracic Society and Centers for Disease Control and Prevention14, 54 
 
Abbreviations: HIV, human immunodeficiency virus; INH, isoniazid; n/a, not applicable; IPT, isoniazid preventive therapy; LTFU, loss to follow-up; mg/kg, milligram per kilogram; ALT, alanine transaminase; AST, 
aspartate aminotransferase; HBsAG, Hepatitis B surface antigen; EBV, Ebstein-Barr virus; HAV, Hepatitis A virus; HBV, Hepatitis B virus; HCV, Hepatitis C virus; CMV, cytomegalorvirus; ULN, upper limit of normal; 
TSB, total serum bilirubin; IQR, inter-quartile range 
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TABLE 4: Liver injury among HIV-infected children receiving isoniazid preventive therapy (IPT) at 10mg/kg daily: 
Authors Study design 
and 
attributes 
INH 
dosage 
and 
duration 
Patient 
numbers, 
ages 
Monitoring Viral hepatitis 
testing 
Clinical 
indicators of 
liver injury 
Study 
definition 
of hepato-
toxicity 
Summary 
of 
laboratory 
findings 
Timing of 
liver injury 
detection 
Risk of 
mild-
moderate 
liver injury 
Risk of 
severe liver 
injury 
Total risk 
of 
liver 
injury 
Outcomes 
Gray 50 
2010 
Retrospective 
cohort 
No placebo 
10mg/kg 
daily for 
up to 24 
months 
112 
children  
median 
(IQR) age 
22 (10-53) 
months 
Laboratory: 
ALT levels 
at 1, 3, 6 
months 
and 6 
monthly 
thereafter 
Tested in those 
with raised ALT: 
HAV+ (1) 
Details of other 
tests not stated 
No 
symptomatic 
cases 
Pediatric 
division of 
AIDS Grade 
III/IV raised 
ALT 
(>5 times 
ULN) 
Peak ALT 
level range 
(346-1467 
U/l) 
Within first 
12 months 
Not stated Grade III/IV 
elevation in 
8/112 
(7.1%) 
Not 
stated 
Treatment interruptions 
in 4 children; all re-
challenged successfully 
No death/hepatic failure 
due to IPT 
% LTFU not stated 
Madhi 28  
2011 
Randomized 
controlled 
trial with 
placebo; 
allocation 
concealment, 
double-
blinded 
Included HIV+ 
and HIV- 
children 
10-20 
mg/kg 
daily for 
2 years 
273 HIV-
infected 
children in 
IPT group; 
Median 
(IQR) age 
97 (91-120) 
days 
Clinical and 
laboratory 
at three-
monthly 
study visits 
including 
AST and 
ALT 
Not stated Not stated Grade III/IV 
increase in 
liver 
enzymes 
(>5x ULN) 
Not stated Not stated Not stated ALT: 1/273 
(0.4%) 
 
AST: 
11/273 
(4%) 
ALT: 
1/273 
(0.4%) 
 
(Placebo 
group, 
5/274 
(1.8%) 
No treatment 
interruptions for 
hepatotoxicity 
No death/hepatic failure 
due to IPT 
LTFU: 34/273 (12.4%); 
placebo group had 7.6% 
LTFU 
Le Roux 49 
2013 
Prospective 
cohort 
Limited initial 
placebo 
10 mg/kg 
daily for 
up to 5 
years 
297 
children,  
Median 
(IQR) age 
23 (9.5-
48.6) 
months 
Laboratory: 
ALT levels 
six-
monthly; 
Clinical: 
three-
monthly 
visits 
Tested in most 
(12/19) children 
with severe 
liver injury: 
HAV+ (5) 
CMV+ (2) 
EBV+ (1) 
No child tested 
positive for HBV 
or HCV 
6/16 cases were 
asymptomatic 
Vomiting, 
diarrhea, 
anorexia, 
malaise, fever, 
cough 
2/16 cases were 
jaundiced 
ALT >10x 
ULN 
Peak ALT 
range: 293-
1761 U/l 
Range: 4 
weeks to 4 
years; 
median 
onset 6 
months 
Not stated All-cause, 
while on 
IPT: 
16/297 
(5.4%) 
 
IPT-related: 
5/297 
(1.7%) 
All-cause, 
while on 
IPT: 
16/297 
(5.4%) 
 
IPT-
related: 
5/297 
(1.7%) 
Treatment interruptions 
in 11/297 (3.7%); 10 
successfully re-
challenged 
No death/hepatic failure 
due to IPT 
% LTFU on IPT not 
stated; overall LTFU 
28/324 (8.6%) 
Abbreviations: HIV, human immunodeficiency virus; INH, isoniazid; ART, antiretroviral therapy; IQR, inter-quartile range; U/l, units per liter; IPT, isoniazid preventive therapy; LTFU, loss to follow-up; mg/kg, milligram per 
kilogram; ALT, alanine transaminase; AST, aspartate aminotransferase; HBsAG, Hepatitis B surface antigen; EBV, Ebstein-Barr virus; HAV, Hepatitis A virus; HBV, Hepatitis B virus; HCV, Hepatitis C virus; CMV, cytomegalorvirus; 
ULN, upper limit of normal; TSB, total serum bilirubin
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b. Intervention & comparison 
Isoniazid was administered at a dose of 5 mg/kg/day in 6 studies4, 37, 43-46 (Table 1), 10 
mg/kg/day in 6 studies32, 33, 38, 40, 42, 47 (table 2) and 10-20 mg/kg/day in 10 studies28, 30, 31, 
34-36, 41, 48, 55 of IPT in HIV-uninfected children (table 3). One retrospective cohort study 
from the US reported outcomes among HIV-uninfected children receiving 20-30 mg/kg 
twice weekly29 (table 3). All studies including HIV-infected children provided IPT at a 
dose of 10 mg/kg/day28, 49, 50 (table 4).  Duration of IPT varied according to the local 
tuberculosis prevention protocols at the time of the study: the most commonly reported 
duration was 12 months of IPT (10 studies)4, 30, 31, 33-36, 38, 39, 41, followed by 9 months (5 
studies)29, 37, 40, 42, 48, 3-6 months (depending on indication for IPT, 4 studies)44-47 and one 
study observed children for the first 3 months of an unspecified duration of therapy. All 
three South African studies conducted among HIV-infected children reported on 
prolonged IPT use, with between 2 and 5 years of IPT exposure28, 49, 50. 
ii. Evaluation of outcomes: Incidence of liver injury 
a. Definition of liver injury 
The definition of “clinically significant” liver injury has been debated and redefined 
several times since the 1970s6, 52, 56-59. Early efficacy studies of IPT in HIV-uninfected 
children reported an extremely low incidence of hepatotoxicity, based on clinical 
assessments4. After wide-spread introduction of IPT in the USA, case reports surfaced 
demonstrating cases of severe hepatitis and even death from hepatic failure among 
both adults and children receiving IPT60, 61. A large and intensive national isoniazid 
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surveillance study (using structured, monthly clinical monitoring) followed in 1972, as 
published by Kopanoff et al in 197430. The same period saw an increased use of serial 
liver enzyme testing to monitor for IPT-related liver injury33, 34, 37, 41, 43, 59. Several studies 
in both adults and children reported what became known as “transient transaminase 
elevation” (TTE), where liver enzymes increase then normalize without any clinical 
symptoms or intervention33, 37, 41, 43, 62.  Studies that defined liver injury only on the basis 
of an increase in serum liver enzymes necessarily reported higher overall rates of liver 
injury than those studies in which liver injury was diagnosed on only clinical outcomes. 
However, as reported by both Palusci40 and Wu32, non-specified or unstructured clinical 
monitoring alone may miss subtle early signs of liver dysfunction, to the detriment of 
the patient.   
Taking into account the likely under-diagnosis of liver injury when using non-structured 
clinical monitoring (using a passive surveillance system, awaiting spontaneous report of 
symptoms by parents) and the likely over-diagnosis  of liver injury when using repeated 
laboratory measures in asymptomatic individuals, international guidelines51, 54, 58 now 
recommend structured clinical monitoring (specifically inquiring about symptoms at 
regular clinical contact, preferably using a structured questionnaire), with laboratory 
testing only in children who are at high risk or have symptoms suggestive of hepatitis. In 
these cases liver injury is defined as a symptomatic case with significantly increased liver 
enzyme tests; a “significant” increase cut off point is commonly set at 3, 5 or 10-fold the 
upper limit of normal (ULN), using either ALT and/or AST, whilst also testing serum 
bilirubin51, 54, 58.  
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Hepatic failure and death are however undisputed indicators of severe liver injury.  Only 
two of the reviewed publications reported death or hepatic failure; both cohorts of 
children had been monitoring clinically only, in an unspecified manner32, 40 (table 2). One 
of 318 (0.3%) patients developed hepatic failure in the retrospective cohort reported by 
Palusci et al; the child survived following liver transplantation40. Wu et al calculated the 
overall risk of IPT-induced liver failure by extracting data from national transplant 
databases, and using the CDC registry of childhood IPT to provide a denominator; the 
estimated risk for IPT-related hepatic failure was 3.2 per 100 000 child-years32. There 
were 5 deaths among the 15 children identified with liver failure, despite receiving liver 
transplants (case fatality ratio, 33%). Despite the outcome assessment bias inherent to 
this calculation, it is notable that all the reports of liver failure and death found in this 
review were among children who received only non-specified clinical monitoring32. 
b. Monitoring of liver injury  
Three broad approaches to toxicity monitoring were identified in the reviewed studies 
(table 5). Two approaches involved primarily clinical monitoring without routine liver 
enzyme testing. In the first approach, identification of clinical hepatitis relied on 
spontaneous parental report of symptoms, without closely spaced clinical visits and/or 
use of structured questionnaires asking about specific symptoms (“unstructured” clinical 
monitoring)4, 32, 36, 45, 46, 48. The second broad approach was to maintain regular patient 
contact with structured, specific toxicity screening questionnaires; additionally, liver 
enzyme tests were conducted in all children with symptoms suggestive of hepatitis 
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(“structured” clinical monitoring, with targeted liver enzyme testing)29-31, 35, 38-40, 42. 
Routine laboratory testing comprised a third approach to monitoring, and was utilized in 
10 studies, including all three studies conducted among HIV-infected children 28, 33, 34, 37, 
41, 43, 44, 47, 49, 63. Liver enzyme tests were conducted at pre-specified intervals during IPT 
exposure, irrespective of symptoms. Generally, higher proportions of children with 
severe liver injury were identified when adverse event monitoring involved either a 
structured clinical approach and/or regular laboratory liver enzyme testing.  
TABLE 5. Liver injury risk estimates for 24 studies by dosage and type of toxicity monitoring: 
 
 TYPE OF MONITORING USED PER STUDY 
ISONIAZID 
DOSE 
Unspecified or unstructured 
clinical monitoring 
Specific clinical monitoring with 
active symptom screening 
Routine laboratory monitoring 
Severe liver 
injury 
Mild-moderate 
liver injury 
Severe liver 
injury 
Mild-moderate 
liver injury 
Severe liver 
injury 
Mild-moderate 
liver injury 
5 mg/kg/day 
None4  
None45  
None46 
0.14%4  
None45 
None46 
- 
 
- 0.6%37  
0.8%43  
None44 
8.4%37 
16.3%43 
None44 
10 mg/kg/day 
3.2/100 000 PY 
32 
Not stated32 0.18%38  
0.3%40  
None42  
 
6.9%38 
3.1%40 
6.5%42 
 
1.1%33  
1.78%47 
7.1%63 
1.7%49 
5.7%33 
0.9%47 
Not stated63 
Not stated49 
10-20 
mg/kg/day 
None36  
None48 
 
0.27%36 
Not stated48 
 
None35  
None39  
None31  
None30 
0.6%35 
None39  
None31 
1 per 1000 PY30 
None41   
None 34  
0.7%28,† 
0.4%28,‡ 
4.3%41 
Not stated34 
Not stated28, † 
Not stated28,‡ 
20-30 mg/kg 
twice weekly 
- - 0.22%29 Not stated29 - - 
Total 
One of 6 (16%) studies describe 
severe liver injury (approximate 
proportion, 0.003%) 
Three of 8 (37.5%) studies 
describe severe liver injury, 
range of risk proportion 
estimates (0.18%-0.3%) 
Eight of 10 (80%) studies describe 
severe liver injury, range of risk 
proportion estimates (0.4% - 
7.1%) 
Numbers are expressed as proportion of children exposed to isoniazid preventive therapy, or as incidence rate per person year of 
exposure, as provided by authors 
† HIV-uninfected group, receiving isoniazid preventive therapy; ‡ HIV-infected group, receiving isoniazid preventive therapy. The 
two groups were enrolled in the same study, reference 28. Abbreviations: mg/kg, milligram per kilogram; PY, person-years 
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c. Dosage and duration of isoniazid 
Among children monitored in an approximately similar manner, those receiving the 
lowest dose (5 mg/kg/day) appeared to have the lowest risk of severe liver injury4, 37, 43-
46 (table 1, table 5). Nonetheless, the relatively higher risks seen in cohorts receiving 
higher doses of IPT were still low in absolute terms (table 2, table 3). Among HIV-
uninfected children, all durations of IPT (3-6 months, 9 months and 12 months) were 
associated with low and similar estimates of risk, and in each category of IPT duration 
there were at least two studies reporting no cases of severe liver injury (table 5). The 
HIV-infected cohorts all received isoniazid therapy for longer than 12 months28, 49, 63. In 
each of these studies some cases of severe hepatotoxicity occurred, but without hepatic 
failure or mortality (table 4); in twelve of the fourteen cases defined as IPT-related 
hepatotoxicity through Grade III/IV elevations in ALT, IPT was successfully restarted 
without further incidence of hepatotoxicity despite close monitoring49, 63. These studies 
were also similar in that all utilized repeated measures of transaminases, despite many 
of the children being asymptomatic. In the absence of randomized comparisons of 
longer vs shorter durations of IPT, it is not possible to reasonably assess the potentially 
increased risk associated with longer isoniazid exposure time. However, in keeping with 
international causality assessment guidelines64-66, liver dysfunction is most likely to be 
drug-induced if it occurs soon after the introduction of the drug. Thus it is possible that 
most cases of DILI will appear in the first few months of IPT, with only some sporadic 
cases in the later months, possibly due to some changes in environmental 
(“downstream”) factors16. As evidence of this, the majority of cases described in the 
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reviewed studies occurred within the first 4 months of IPT29, 32, 33, 37, 38, 40, 41, 43, 49, 50 
(tables 1-4). 
d. Comparison of liver injury risk in HIV-infected vs. HIV uninfected children 
Estimates of severe liver injury risk varied between the three studies conducted in HIV-
infected children. The retrospective cohort reported by Gray et al described the highest 
overall estimate of severe liver injury (7%), but this included several cases where liver 
dysfunction was caused by infectious agents50.  While 1.7% of children developed severe 
liver injury reasonably related to IPT in the cohort study reported by le Roux et al, not all 
children were screened for viral hepatitis, and all but one child subsequently tolerated 
IPT; thus the true incidence was likely lower49. The RCT conducted by Madhi et al found 
no difference in incidence of severe liver injury comparing HIV-infected children 
receiving IPT to those receiving placebo, with an overall 0.4% estimate of severe liver 
injury based on serial measurements of ALT28 . Ninety-eight percent of these HIV-
infected children were also receiving ART. This study further compared risk of severe 
liver injury between HIV-infected and HIV-uninfected children receiving IPT (0.4% and 
0.7% respectively), and found no significant difference between these groups either28. 
Thus although there are limited study numbers, with relatively small sample sizes, in 
general HIV does not appear to confer a higher risk of IPT-related DILI, even in the 
presence of ART.  
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iii. Potential threats to validity 
Apart from one study set in a juvenile detention setting37, selection bias is likely to have 
occurred in the observational studies (21 of 24), where participants who were choosing 
to attend clinical care, were mostly adherent, and not lost to follow-up, contributed the 
largest proportion of exposure time. Apart from the studies by Nolan39 and Cruz29, 
proportions of and reasons for loss to follow-up were either not stated or not evaluated. 
It is possible that those children with higher incidence of hepatitis may have been more 
likely to stop attending care. Similarly, poor adherence is often the result of unpleasant 
side effects; in these instances selection bias due to informative censoring would have 
resulted in an underestimation of the true risk of liver injury. Although it can be argued 
that the children who were more adherent had longer IPT-exposure time and therefore 
should represent those at highest risk, thereby implying that the risk estimates could 
have been overestimations, this is less likely given the increased likelihood of DILI in the 
early weeks of therapy, when most children were still in follow-up15, 66. 
Information bias due to misclassification of children who did/did not experience liver 
injury is highly likely in the studies where monitoring was inadequate (under-estimation 
of risk among children monitored clinically in an unspecified way, or conversely, 
overestimation among asymptomatic children with mild liver enzyme elevations). 
Similarly, as liver injury may wax and wane, studies employing infrequent monitoring 
are also likely to underestimate liver injury, incorrectly classifying children who had 
experienced liver injury in the interim period as not having had a liver injury. 
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Attribution of causality is notoriously difficult in DILI15, 66. In the absence of placebo 
comparison, attributing liver dysfunction to isoniazid exposure is complicated by other 
(often undiagnosed) causes of hepatitis. Of particular interest in these studies was the 
high incidence of viral hepatitis in vulnerable children. In studies where viral causes 
were not excluded, misclassification bias due to inappropriate attribution of causality 
would falsely inflate the true risk of IPT-induced hepatitis. 
iv. Limitations of the review 
The use of only published literature, in only English, limits the quality of the literature 
search. As with any review limited to published studies, publication bias is a concern. 
Early trials of IPT were focused on addressing the urgent public health need to reduce 
incident tuberculosis. Hepatotoxicity was considered a minor concern, and data 
regarding safety and tolerability may not have been published readily given the 
optimism regarding IPT.  However, as the risk has appeared consistently low over 
several decades, it is unlikely that a wider search would have yielded results to 
drastically change the conclusions. Case reports are usually included in review of 
interventional harms; however, the main aim of this review was to summarize 
estimated risks, for which case reports are not suitable, given the lack of denominator. 
Literature reviews of harm are also prone to selective reporting bias; it is possible that 
other trials of IPT chose not to report on liver injuries. A gray literature search would 
have allowed better estimation of selective reporting. This review does however include 
the most prominent national surveillance estimates, where harm was specifically looked 
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for; selective underreporting of other, smaller and less well-conducted trials would be 
unlikely to alter the conclusions of this review. Given the heterogeneity of monitoring 
and liver injury definitions used, outcome assessment bias is highly likely, especially in 
the retrospective studies. However, the monitoring and to a lesser degree the 
definitions of liver injury were aligned with national and international guidelines of 
tuberculosis prevention at the time of the research. The lack of placebo-controlled 
studies, and heterogeneity of methods precluded meaningful meta-analysis. However, 
much toxicity literature depends on post-marketing reports, and given the efficacy of 
IPT in children, placebo controls would have been unethical in most of the research 
settings.  
2.4 CONCLUSIONS AND IMPLICATIONS 
Although great heterogeneity exists between studies, a large amount of data is available 
on IPT-related DILI in HIV-negative children, for a variety of dosages and schedules. 
Overall, severe liver injury occurs infrequently, especially in the very young children who 
are at highest risk for TB disease progression and death. 
Data on IPT-related liver injury in children with HIV is however limited. Three papers 
taken together indicate a low incidence, with no deaths or hepatic failure. However, 
these three publications report comparatively small numbers of children.  Two of the 
three studies were clinical trials; there are no data from routine operational settings 
where monitoring for adverse events is less intense than in clinical trials.  There is 
suggestive evidence that IPT in HIV-infected children, even in combination with ART, is 
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not associated with substantially higher risk of DILI compared to HIV-uninfected 
children; however risk-benefit evaluation of long-term IPT in children with advanced HIV 
disease who commence ART is not yet possible. There is a need for larger, prospective 
evaluations of the impact and risks of IPT in addition to ART, given under routine clinical 
conditions.  
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1. Summary 
SETTING:  Two pediatric hospitals in Cape Town, South Africa 
OBJECTIVE:  To investigate the incidence, predictors and outcomes of severe liver injury in HIV-
infected children receiving long-term isoniazid preventive therapy (IPT). 
DESIGN:  Randomized trial of IPT or placebo given daily or thrice-weekly to HIV-infected 
children aged ≥8 weeks; placebo was discontinued early. Alanine transaminase (ALT) was 
measured at baseline, six-monthly and during illness: an increase ≥10-fold the upper limit of 
normal defined severe liver injury. 
RESULTS:  Of 324 children enrolled, 297 (91.6%) received IPT (559.1 person-years). Baseline 
median age was 23 months (interquartile range, IQR 9.5-48.6) and median CD4%, 20% (IQR 
13.6-26.9). Two-hundred-and-seven children (63.9%) received antiretroviral therapy (ART). 
Nineteen developed severe liver injury, sixteen while receiving IPT. Among these were eight 
cases of viral hepatitis (five with hepatitis A), two antiretroviral-induced liver injuries and a case 
of abdominal tuberculosis. IPT-related severe liver injury occurred in 1.7% (5/297, 0.78/100 
person-years). No child developed hepatic failure; one died of an unrelated cause. All surviving 
children subsequently tolerated IPT.  
CONCLUSIONS:  This study suggests that long-term IPT has a low toxicity risk in HIV-infected 
children. In the absence of chronic viral hepatitis, IPT can be safely reintroduced following 
recovery from liver injury.  
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2. Manuscript 
2.1 INTRODUCTION  
The World Health Organization (WHO) has identified isoniazid preventive therapy (IPT), 
intensified case finding and infection control as key to reducing tuberculosis (TB) incidence 
among people living with HIV1. Current guidelines recommend six months of IPT for HIV-
infected children older than one year without TB disease, even in the absence of a known TB 
contact; up to three years is recommended in high TB prevalence areas2, 3. 
However, isoniazid may cause idiosyncratic drug-induced liver injury (DILI)4. Its predominant 
metabolizing pathway is acetylation by N-acetyl transferase 2 (NAT2); toxicity is mostly 
attributed to metabolites4. Idiosyncratic DILI is thought to result from a complex “multi-hit” 
process, where drug-specific upstream injury is exacerbated or ameliorated by less specific 
downstream factors5, 6. Drug-specific risk factors for IPT-related liver injury include higher 
dosages and polymorphisms of NAT24, 7. During TB treatment, daily dosing appears to confer 
higher risk than intermittent dosing4. Downstream factors include malnutrition, other 
hepatotoxic drugs (such as nevirapine and pyrazinamide), viral hepatitis, and in adults, age and 
alcoholism. Although widely considered a risk factor, the independent effect of HIV-infection is 
not yet fully established8. Severe hepatitis occurred in only 1.1% of HIV-infected adults 
receiving six months of IPT in Botswana9; this estimate is comparable to the 0.1%-6.4% risk 
described in large studies of HIV-uninfected adults9-11. Nonetheless, it is biologically plausible 
that the altered cytokine milieu of chronic viral infection may predispose to idiosyncratic DILI 5.  
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In keeping with this, a recent study observed severe liver injury in 5.5% of HIV-infected adults 
receiving 6 months of IPT12. Children generally tolerate isoniazid better than adults. Although 
death and hepatic failure can occur13, only 0.8% or less of HIV-uninfected children experience 
moderate to severe liver injury4, 9, 14-16. Data for HIV-infected children are limited. One 
retrospective study reported severe liver injury in 5% of 112 HIV-infected children receiving IPT, 
mostly ascribed to acute viral hepatitis17. In a recent South African trial, HIV-infected infants 
received IPT for up to two years; 0.4% developed significantly raised alanine transaminase 
(ALT), and 4.0% significantly raised aspartate aminotransferase (AST)18.  However, there are no 
published, prospective long-term data on liver injury in HIV-infected children older than one 
year or in symptomatic HIV-infected children who commence IPT. As some risk factors are 
dynamic, the cumulative risk for IPT-related liver injury may increase over longer exposure 
periods, as was observed among HIV-infected adults receiving three to six years of IPT12, 19. We 
investigated the incidence, predictors and outcome of severe liver injury in a cohort of HIV-
infected infants and children receiving long-term IPT. 
2.2 METHODS 
A prospective study of opportunistic infection prevention strategies in HIV-infected children 
commenced in December 2002, at Red Cross and Tygerberg Children’s Hospitals in Cape Town, 
South Africa. The trial had a factorial design with two levels of randomization: participants were 
randomized to receive either isoniazid with trimethoprim-sulphamethoxazole (TMP-SMX) or 
placebo with TMP-SMX and again randomized to either a daily or thrice-weekly dosing 
schedule, figure 1. Placebo was discontinued in May 2004, due to a marked survival benefit 
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among children receiving IPT20. Thereafter, all children receiving placebo were switched to IPT 
and followed until December 2007 to assess potential differences in efficacy, safety and 
adherence.  
i. Participants and allocation 
HIV-infected children aged ≥ eight weeks were enrolled. Exclusion criteria, previously 
described20, 21, included clinical hepatitis. Children receiving antiretroviral therapy (ART) were 
eligible once stable on treatment for at least two months. Enrolment, allocation and 
randomization processes are described elsewhere20, 21.  
ii. Medication 
Isoniazid tablets (100 mg, Be-Tabs Pharmaceuticals, Johannesburg, South Africa) were given at 
10 mg/kg per dose (range of 8-12mg/kg, maximum 300mg), for both dosing schedules.  
Allocation was unblinded in children with TB disease. Those receiving placebo commenced 
standard anti-TB treatment for children (WHO regimen 3, isoniazid/rifampicin/pyrazinamide); 
those randomized to IPT also started ethambutol or ethionamide. Treatment was modified 
according to antimicrobial susceptibility. The South African government commenced 
antiretroviral roll-out in 2004 where after ART became available to all.  
iii. Measurements 
HIV status was assessed by enzyme-linked immuno-sorbent assay (Abbott AxSYM HIV 
antibody/antigen ELISA) in those older than 15 months, and by polymerase chain reaction (PCR, 
Amplicor HIV-1, Roche Diagnostic Systems) in those younger. Alanine aminotransferase (ALT) 
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was measured at baseline and six-monthly; children on ART also had measurements one and 
three months after enrolment.  Other regular investigations have been described20, 21. Tests 
were repeated whenever clinically indicated. Children were not routinely screened for viral 
hepatitis at enrolment.  All deaths were investigated by accessing clinical records, or if 
unavailable, by verbal autopsy where feasible.  
Toxicity events were graded according to the Division of AIDS (DAIDS) toxicity criteria22. For liver 
injury, ALT 10-15 times the upper limit of normal (ULN) was considered grade three; above 15-
fold increase was considered grade four. Children with grade three or four events were urgently 
recalled and assessed, with repeat ALT, aspartate transaminase (AST) and total bilirubin testing. 
Isoniazid was discontinued and further investigations were guided by clinical condition on 
advice from gastroenterology and/or infectious diseases specialists. Additional tests included 
alkaline phosphatase, gamma-glutamyltransferase, albumin, conjugated bilirubin, prothrombin 
time and lactate dehydrogenase. Etiological investigations included screening for hepatitis A 
(HAV, IgM and IgG), hepatitis B (HBV, antigen and antibodies) and hepatitis C virus (HCV, 
antibodies); Ebstein-Barr virus (EBV, IgM and IgG) and/or cytomegalovirus (CMV IgM, IgG 
antibodies, pp65 assay and/ or urine CMV culture). Abdominal ultrasound was available when 
indicated. For clinically severe or life-threatening events, participants were hospitalized and 
ART was interrupted.  Most participants were managed as outpatients, with repeat ALT after 48 
hours, two to four-weekly for a month then monthly until the levels were less than 3 times the 
ULN. Caregivers were requested to return immediately if children became symptomatic.  After 
clinical and biochemical recovery, drugs were systematically reintroduced: isoniazid was 
restarted after the successful reintroduction of ART and TMP-SMX. Rechallenge with IPT 
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occurred at full dose, with two-to four-weekly follow-up and instructions to return immediately 
if symptomatic. Anti-TB therapy and/or ART were reintroduced in hospital, according to 
hospital protocol: antiretrovirals were started simultaneously and anti-TB drugs introduced 
systematically. Each event was assessed as definitely, probably, possibly or unrelated to study 
drugs, and notified to the relevant ethics committees. 
iv. Ethics 
Written, informed consent was obtained from a parent or legal guardian. The Research and 
Ethics Committees of the Universities of Cape Town and Stellenbosch approved the study. The 
trial is registered as Clinical Trials NCT00330304. 
v. Statistical methods 
The main outcome was severe liver injury, defined as a grade three or four elevation in ALT 
during follow-up. The Kaplan-Meier method was used to analyze time to severe liver injury. 
Person-time was censored at the first event or last known time alive, if event-free.   
Crude incidence rate ratios (IRR) were used to compare dosing schedule (intent-to-treat 
analysis) and categories of drug exposure (as-treated analysis). Potential predictors were 
analyzed with Cox proportional hazards regression. Baseline age was dichotomized at one year. 
Exposure to ART and anti-TB drugs (placebo, IPT or anti-TB treatment) were modeled as time-
varying covariates. Standard statistical methods were used for model building and checking. 
Analyses were done in Stata version 10.0 (Stata Corporation, College Station, Texas, USA). 
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Statistical tests were two-sided at alpha=0.05. Sample size calculations for mortality, the 
primary outcome of the main study, have been described elsewhere20, 21 
2.3 RESULTS 
Of 339 children randomized, 15 were excluded from analysis (10 tested HIV-negative, five were 
lost to follow-up within the first month).  Three-hundred-and-twenty-four were followed for 
641 person-years. Baseline characteristics are shown in table 1. Two hundred and ninety-seven 
received IPT (559.1 person-years, table 2): 99 had been switched from placebo, figure 1. 
Adherence was excellent and similar in the groups, as previously reported23.  
i. Incidence rates and clinical presentation 
Overall, nineteen (6%) of 324 children had an episode of severe liver injury (2.96 first episodes 
per 100 person-years), table 2. Most were young (median baseline age 14 months, IQR 5.00-
36.18). The median baseline CD4% was 23% (IQR 19.02-31.00). Ten (53%) had symptoms 
typically associated with hepatitis. Vomiting was the most frequent complaint; two children 
were jaundiced. No child developed hepatic failure. Details are provided in appendix 1.   
One event occurred on placebo (incidence rate, IR 1.7 per 100 person-years), 16 on IPT (IR 2.86 
per 100 person-years; 16/297, 5.4%) and two on anti-TB treatment (IR 8.64 per 100 person-
years; 2/34, 5.9%), table 2.  The IRR comparing IPT and ART to only ART was 0.29 (95% CI 0.038– 
12.87). There was a trend towards decreased risk in the thrice-weekly arm, table 2. The median 
time to severe liver injury was 16.4 months (IQR 5.2-23.6); only four events occurred within the 
first four months of IPT exposure.  
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Fourteen (74%) episodes of severe liver injury were considered unrelated to IPT: eight children 
had acute viral hepatitis (five HAV, one EBV and two CMV). Five children had severe liver injury 
within 3 months of starting ART or anti-TB treatment; one was diagnosed with abdominal TB. 
Thus only five (1.7%) of the 297 children who received IPT did not have another compelling 
cause for liver injury identified. All five had received daily IPT.  
ii. Outcomes 
The average time to normalization of ALT (≤ 3-fold ULN) was 36 days (range 6-84 days). In eight 
children, the repeat ALT was lower than 10-fold ULN; IPT was continued under close 
supervision. All improved with no recurrence. IPT was discontinued in 11 children: ten were 
successfully rechallenged. One child died from hypoxic pneumonia before IPT was restarted. No 
further episodes of severe liver injury were experienced, except for one child who subsequently 
contracted and recovered from hepatitis A.  
iii. Cox proportional hazards regression 
Baseline ALT and nutritional status were not associated with the outcome. Younger baseline 
age [adjusted hazard ratio (aHR) 3.47 (95% CI 1.27-9.47)] and higher baseline CD4% [aHR 1.06 
(95%CI 1.01-1.12)] were significantly associated with severe liver injury, table 3. 
2.4 DISCUSSION  
Whereas a large number of children (16/297, 5.4%) developed severe liver injury whilst 
receiving IPT, only a few cases (5/297, 1.7%) were reasonably related to IPT. Non-drug causes 
were found in nine and rechallenge was uneventful in all survivors. Causality assessment in DILI 
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is notoriously difficult6, 24; several algorithms and clinical scales have been proposed to aid 
diagnosis25. Most clinical scales strongly weigh exclusion of non-drug causes, temporal 
association with starting the drug in question and response to rechallenge in the probability 
scoring for diagnosis of DILI 24, 26, 27. Response to rechallenge is considered the closest there is to 
a “gold standard”6, 26. Therefore it is possible that we overestimated the true incidence of IPT-
induced liver injury.  
Similar or higher rates of liver injury were observed in two recent studies of HIV-infected adults 
receiving IPT9,13,20. The only other published, prospective study of pediatric IPT, given to HIV-
infected infants for up to two years, observed severe liver injury in 0.4% of infants18. The data 
therefore indicate that, as seen in HIV-uninfected populations, risk for IPT-related severe liver 
injury is lower in HIV-infected children than in HIV-infected adults. Although not negligible, this 
degree of risk has been considered acceptable in the risk-benefit assessment of IPT for adults at 
high risk for TB disease progression3. Quantitative risk-benefit analyses are lacking, but effective 
tuberculosis prevention via IPT offers substantial benefit to HIV-infected children, who have a 
particularly high risk for TB disease progression, morbidity and mortality, even in the context of 
ART 2, 20, 28. This study further demonstrates that IPT can be safely re-introduced after severe 
liver injury has resolved. 
We found a high incidence of viral hepatitis, particularly HAV. South Africa is highly endemic for 
HAV, with an estimated seroprevalence of 83% among infants29, 30 Unfortunately, HAV vaccine 
is not in the national immunization program. South African children have been routinely 
immunized against HBV since 1995, and the prevalence of HCV is thought to be low 31. As these 
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viruses share transmission routes with HIV, the impact of viral hepatitis on the care of HIV-
infected children from other resource-limited settings might be even greater32.  
Most study participants received ART during the trial. In keeping with adult data from 
Botswana33, we did not observe a higher incidence of liver injury among children receiving both 
ART and IPT compared to ART only. Unfortunately, our estimates lack precision, and data from 
larger cohorts will be required to confirm this finding.   
Transient rises in ALT commonly occur during treatment with isoniazid, without apparent 
clinical significance6, 8; consistent with this, some children with grade three or four liver injury 
rapidly improved to grade two or less before IPT could be interrupted, without further 
increases in ALT. Previous guidelines on IPT recommend biochemical monitoring for high-risk 
groups only 8. Our study has identified two potentially high risk pediatric groups, namely the 
very young and those with high CD4%. 
Generally, children are at low risk for isoniazid-related liver injury, and studies of pediatric IPT 
have seldom examined differential risk across age subgroups.  However, one pediatric study 
described higher risk for TB-drug-induced liver injury among children younger than 5 years34. As 
young children have immature enzyme systems, it is biologically plausible that infants are at 
increased risk of isoniazid-induced liver injury. In HAV-endemic areas, infants may also be at 
highest risk for HAV infection. 
We found higher baseline CD4% to be associated with liver injury. Both adaptive and innate 
immune responses are involved in the processes that can lead to isoniazid-induced liver injury5. 
Higher CD4% might be a surrogate marker for overall better preserved immunity, paradoxically 
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placing healthier individuals at higher risk for toxicity. Furthermore, isoniazid has been shown 
to cause cell death via apoptosis35; the effectiveness of cytotoxic T-cell function might influence 
the extent of final liver injury.    
Our study has limitations. The discontinuation of placebo restricts the evaluation of isoniazid-
attributable hepatotoxicity. By definition, idiosyncratic DILI is uncommon; with only 19 events, 
statistical power was limited. While point estimates indicated higher risk for IPT compared to 
placebo, and daily IPT compared to-thrice-weekly, the results are inconclusive due to 
imprecision. 
Although we explored a range of risk factors, NAT2 genotyping was not performed; possibly 
those with liver injury were slow acetylators7, 35. 
The continuation of isoniazid despite symptomatic, severe liver injury can be fatal13. We were 
able to diagnose hepatotoxicity early with prompt interruption of IPT and careful re-
introduction where indicated; we also re-assessed patients frequently, and did extensive viral 
hepatitis screening. This level of risk management may be challenging in operational settings.  
2.5 CONCLUSION 
This study suggests that long-term IPT has a low hepatic toxicity risk in HIV-infected children. In 
the absence of chronic viral hepatitis, IPT can be safely reintroduced following recovery.   
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FIGURE 2. Flow of participants through trial 
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Reasons for withdrawal: 
Relocated (n=10) 
Maternal request (n=6) 
Started ART (n=1) 
Other (n=1) 
 
Allocated to 
 Isoniazid 
(n=104) 
 
 Enrolled before  
May 2004 
       (n=70) 
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        (n=69) 
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Placebo 
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switched to 
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Placebo  
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TABLE 6.  Baseline characteristics of children randomized to thrice weekly or daily isoniazid/placebo and 
trimethoprim-sulphamethoxazole 
 
Thrice weekly  
(n=165) 
Daily  
(n=159) 
Total  
(n=324) 
Allocated to placebo1 42.4% (70) 40.0% (62) 40.7% (132) 
Allocated to isoniazid 
    Before May 2004 
    After May 2004 
 
40.6% (67) 
17.0% (28) 
 
40.2% (64) 
20.8% (33) 
 
40.4% (131) 
18.8% (61) 
Age  
(months)  
21.8 (9.5 – 52.3) 24.6 (9.7 – 45.6) 23.0 (9.5 – 48.6) 
Boys  56.9% (94) 54.7% (87) 55.8% (181) 
Weight for age  
(z-score)  
-1.3 (-1.8 to -1.0) -1.6 (-1.9 to -1.2) -1.5 (-1.8 to -1.2) 
ALT  
(U/l)  
28 (20.5 – 41.5) 27 (17 – 43) 28 (18 – 42) 
CD4  
(% lymphocytes)  
20.4 (14.3 – 28) 19.0 (12.1 – 25.2) 20.0 (13.6 – 26.9) 
ART 
  At enrolment 
  Ever during study 
 
8.5% (14) 
63.0% (104) 
 
8.8% (14) 
64.8% (103) 
 
8.6% (28) 
63.9% (207) 
Figures are % (number), or median (interquartile range); Abbreviations: ALT, alanine transaminase; ART, antiretroviral therapy 
1 Children were only allocated to placebo until May 2004 
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TABLE 7.  Incidence rates of severe liver injury by group and per drug exposure category 
 
Not on ART  On ART  TOTAL 
Number 
of 
events 
Time 
(years) 
Incidence 
rate per 100 
child-years 
Number 
of 
events 
Time 
(years) 
Incidence 
rate per 100 
child-years 
Number 
of 
events 
Follow-
up time 
(years) 
Incidence 
rate per 100 
child-years 
Incidence rate 
ratio (95%CI) 
Dosing schedule   
      Daily dosing 4 135.0 2.96 8 164.0 4.88 12 299.0 4.01 1 
     Thrice weekly dosing 5 168.8 2.96 2 173.2 1.15 7 341.96 2.04 
0.51 
(0.2-1.4) 
   
Drug exposure category   
Placebo 0 47.3 0 1 11.5 8.71 1 58.8 1.7 1 
IPT 8 242.7 3.30 8 316.4 2.53 16 559.1 2.86 1.68 (0.3-70.6) 
Anti-TB treatment 1 13.8 7.24 1 9.3 10.7 2 23.1 8.64 
5.09 
(0.3-299.8) 
Total 9 303.8 2.96 10 337.2 2.97 19 641.0 2.96 - 
Abbreviations: CI, confidence interval; IPT, isoniazid preventive therapy; TB, tuberculosis; ART, combination antiretroviral therapy  
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   TABLE 8.  Factors associated with severe liver injury: unadjusted and adjusted hazard ratios from Cox proportional hazards regression 
Variable 
Unadjusted 
 
Adjusted* 
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value 
  
Dosing schedule  
     Daily 1.00 - - 1.00   
     Thrice weekly 0.50 0.20-1.28 0.15 0.44 0.17-1.15 0.09 
  
Age at baseline  
    > 12 months  1.00 - - 1.00 - - 
    ≤ 12 months 3.20 1.29-7.95 0.01 3.47 1.27-9.47 0.02 
  
CD4% at baseline§ 1.04 1.00-1.09 0.05 1.06 1.01-1.12 0.01 
* Adjusted for dosing schedule, baseline age, baseline CD4%, study site, current exposure to ART and current TB drug exposure 
§ Missing data for 7 children 
ART, antiretroviral therapy; TB, tuberculosis
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Nr 
Study 
drugs* 
Dosing 
Time exposed 
to isoniazid 
(months) 
Other drugs 
Time on 
ART 
(months) 
Clinical presentation 
Highest 
ALT (U/l) 
Viral hepatitis†  
screen performed 
Diagnosis‡ Outcome 
Time to resolution/ 
rechallenge (days) 
1 Isoniazid Daily 3.64 None 0 Anorexia, malaise & cough 1575 Not done Isoniazid DILI 
(possible) 
Recovered 23 
2 Isoniazid Daily 11.74 None 0 Asymptomatic 490 Not done Isoniazid DILI 
(probable) 
Recovered 39 
3 Isoniazid Daily 17.1 3TC/D4T/ 
LPV/r 
21.11 Asymptomatic 857 HAV, HBV Isoniazid DILI 
(possible) 
Recovered 73 
4 Isoniazid Daily 24.03 None 0 Asymptomatic 413 HAV, HBV, HCV, 
EBV, CMV 
Isoniazid DILI 
(possible) 
Recovered 28 
5 Isoniazid Daily 52.79 3TC/D4T/NVP 33.44 Vomiting 1306 Not done Isoniazid DILI 
(possible) 
Recovered 84 
6 Isoniazid 3xWk 5.64 None 0 Vomiting, diarrhoea 
& fever 
1761 HAV Hepatitis A1 Recovered 32 
7 Isoniazid 
 
3xWk 10.65 None 0 Jaundice 3138 HAV, HBV, HCV Hepatitis A1 Recovered 53 
8 Isoniazid Daily 21.57 3TC/AZT/ 
LPV/r 
6.26 Cough & fever 482 HAV, HBV Hepatitis A1 Recovered 14 
9 Isoniazid 
 
Daily 23.57 3TC/AZT/RTV 15.64 Asymptomatic 633 HAV, HBV Hepatitis A1 Recovered 21 
10 Isoniazid Daily 23.77 3TC/D4T/EFV 19.5 Asymptomatic 872 HAV, HBV, HCV 
CMV, EBV 
Hepatitis A1 Recovered 9 
11 Placebo Daily 0 3TC/AZT/RTV 2.20 Cough 293 Not done ART DILI Recovered 56 
12 Isoniazid Daily 4.72 3TC/AZT/EFV 3.08 Vomiting 651 Not done ART DILI Recovered 62 
13 Isoniazid 3xWk 9.44 3TC/AZT/EFV 1.25 Vomiting, diarrhoea 405 Not done ART DILI Recovered 30 
14 Isoniazid Daily 6.45 None 0 Asymptomatic 373 HAV, HBV, HCV 
CMV, EBV 
EBV hepatitis2 ⁪ Recovered 28 
15 Isoniazid 3xWk 2.62 3TC/AZT/RTV 
Fluconazole 
3 days Vomiting, anorexia, failure to thrive, 
jaundice, fever, diarrhoea & cough 
557 HAV, HBV, HCV 
CMV, EBV 
Disseminated 
CMV 
with hepatitis3 ⁫ 
Recovered 14 
16 Isoniazid 3xWk 1.02 Erythromycin 0 Vomiting, jaundice 
cough & fever 
356 HAV, HBV 
CMV 
CMV hepatitis4 ⁬ Died: CMV 
pneumonia 
- 
17 (TB 
treatment) 
Daily 5.04 TB treatment§ 
3TC/D4T/EFV 
Fluconazole 
1.08 Vomiting 
& fever 
421 HAV, HBV, HCV Anti-TB DILI Recovered 6 
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Abbreviations: 3XWk – Thrice weekly; ALT – alanine aminotransaminase; cART – combination antiretroviral therapy; DILI – drug induced liver injury; 3TC – lamivudine; D4T – stavudine; AZT – zidovudine; Lopinavir/ritonavir – LPV/r; RTV – 
Ritonavir; NVP – nevirapine; EFV – efavirenz; HAV – Hepatitis A virus; HBV – Hepatitis B virus; HCV – Hepatitis C virus; CMV – cytomegalovirus; EBV – Ebstein Barr virus; TB – tuberculosis 
*All received trimethoprim-sulphamethoxazole according to the dosing schedule for isoniazid/placebo 
⁪†Viral hepatitis screening: unless otherwise indicated, screening tests were – IgM and IgG antibodies for HAV, EBV and CMV; surface antigen for HBV; antibodies for HCV  
‡Diagnosis based on:  
1. Positive Hepatitis A IgM antibody;  2. Positive EBV Viral capsid antigen IgM;  
3. Positive pp65, positive CMV viral culture from urine; clinical CMV retinitis; 4 Positive pp65, positive CMV IgM and IgG with CMV pneumonia on lung biopsy 
§Isoniazid/rifampicin/pyrazinamide/ethionamide (hepatotoxicity occurred after 90 days)  
#Isoniazid/rifampicin/pyrazinamide/ethionamide (hepatotoxicity occurred after 53 days) 
 
 
Nr 
Study 
drugs* 
Dosing 
Time exposed 
to isoniazid 
(months) 
Other drugs 
Time on 
ART 
(months) 
Clinical presentation 
Highest 
ALT (U/l) 
Viral hepatitis†  
screen performed 
Diagnosis‡ Outcome 
Time to resolution/ 
rechallenge (days) 
18 (TB 
treatment) 
3xWk 8.20 TB treatment# 0 Asymptomatic 398 Not done Anti-TB DILI Recovered 7 
19 Isoniazid 3xWk 3.64 Omeprazole 0 Vomiting, diarrhoea & fever 1290 HAV, HBV, HCV 
EBV 
Abdominal TB Recovered 68 
